Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
OncoCyte (OCX) just unveiled an announcement.
Oncocyte Corporation has appointed Andrea James as their new Chief Financial Officer and Principal Financial Officer, effective June 17, 2024. With a rich background in investor relations and corporate strategy, including senior roles at Axon Enterprise and strategic consultancy for Tesla, Inc., Ms. James brings a wealth of experience to the role. Her compensation includes a $325,000 base salary, with a potential annual bonus of 50%, along with comprehensive severance and equity terms. James has no familial ties to the company’s executives and her appointment is independent of any other agreements.
For detailed information about OCX stock, go to TipRanks’ Stock Analysis page.
